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Abstract 
Retrotransposons tune immune reactivity in differentiated cells because when 
they are transcribed, their nucleic acids can be viewed as non-self leading to 
innate immune sensing. Most retrotransposons, however, are subject to 
transcriptional regulation by a multitude of epigenetic pathways, which have 
coevolved with them for millions of years. While a lot is known about the 
epigenetic control of retrotransposons in germ cells and early embryos, 
surprisingly little is understood about these pathways in adult tissues, 
particularly in human cells. Recent evidence suggests that retrotransposon 
repression persists in differentiated cells and is dynamic. Future insight into this 
topic may teach us how to reactivate or silence specific retrotransposon families, 
to promote anti-tumour immunity or dampen autoimmunity through epigenetic 
modulation. 
 
Introduction 
Transposable elements (TEs) are mobile genetic elements aptly named 
“controlling elements” by Barbara McClintock in the 1950s because of their 
ability to control cellular genes [1]. Since their discovery, the advancement of 
genome sequencing and bioinformatics technologies has led to the identification 
of a huge number of TE families, the functions of which are now being unraveled. 
Retrotransposons are particularly relevant TEs because they can replicate 
through an RNA intermediate, allowing them to insert new DNA copies of 
themselves into the genome. This has enabled them to accumulate over millions 
of years and they now comprise more than half of the human genome[2]. Over 
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time, deleterious insertions are negatively selected while those beneficial to the 
host become co-opted and fixed in the genome[3]. Co-opted retrotransposons 
are often from the endogenous retrovirus (ERV) class, which dates back 
hundreds of millions of years [4]. Although retrotransposons are overall 
beneficial as a driving force behind the evolution of new genes and non-coding 
DNA[5, 6], they can also compromise genome and transcriptome integrity [7]. A 
multitude of epigenetic pathways, therefore, act in early development to 
constrain their transcription and some of these strategies remain active in 
differentiated cells. 
 
Epigenetics refers to modifications on chromatin, rather than DNA sequence 
alterations, which lead to heritable effects on gene expression. Chromatin is 
subject to histone modifications and cytosine methylation and distinct epigenetic 
marks are associated with an active and silent gene expression state. For 
example, acetylation of histone 3 at the lysine residue at position 27 (H3K27ac) 
is a chromatin signature associated with active genes and enhancers[8], whereas 
trimethylation of histone 3 at the lysine at position 9 (H3K9me3) correlates with 
heterochromatin and gene silencing[9-11]. Retrotransposons direct both genetic 
and epigenetic heritable traits because they can integrate into our genome in the 
germ line and orchestrate epigenetic alterations through the recruitment of 
transcription factors to their regulatory elements [12]. 
 
Since half of the human genome is derived from retrotransposons, it can be 
viewed as non-self. Although most human retrotransposons are no longer 
mobile, expression of their nucleic acids and proteins can lead to the formation 
of pathogen-associated molecular patterns (PAMPs) and antigens that we refer 
to here as “neo-antigens” that could potentially elicit an immunological response. 
Retrotransposons, are therefore situated at the interface of immune reactivity; 
when enriched in silent chromatin they are transcriptionally inactive and 
immune masked, whereas when expressed they may trigger innate and adaptive 
immunity [13-15]. In this review, we will discuss the mechanisms in place to 
maintain retrotransposons silent in differentiated cells and the implications of 
these pathways. We will focus here on chromatin readers, writers and erasers 
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and the KAP1 and KRAB-ZNF system. The role of small RNAs, while important, is 
beyond the scope of this review and we direct the reader to a recent review 
covering this topic[16].  
 
Epigenetic pathways constraining retrotransposons 
Epigenetic silencing of retrotransposons takes place in early embryos and in 
differentiated tissues, epigenetic states link back to patterns established during 
development[17]. The identification of factors that maintain repression in 
postembryonic tissues and how dynamic chromatin marks are in differentiated 
cell types is a fascinating and emerging area of research. Moreover, existing work 
relies largely on mouse models so it will be crucial to establish parallels in 
human cells, where the precise retrotransposons, their activity and their 
coevolution patterns with genes are distinct[18]. 
 
Chromatin readers, writers and erasers 
Chromatin-associated proteins induce epigenetic changes to either histones or 
DNA and mediate downstream biological functions. Promoter cytosine 
methylation occurs at ERVs and is associated with gene repression [19, 20], 
whereas intragenic methylation prevents spurious transcription initiation [21]. 
Interestingly, human ERV-K (HERV-K) genomic sequences have undergone 
selection to mutate CpG dinucleotides, presumably to escape repression through 
DNA methylation [22]. De novo methylation is carried out by DNMT3A, DNMT3B, 
the newly discovered rodent-specific DNMT3C, and the cofactor DNMT3L [23-
26] and maintained by DNMT1 through cell divisions [27, 28]. Defective DNMT1 
leads to DNA hypomethylation and ERV overexpression and plays a causative 
role in the onset of cancer and autoimmune disease [29, 30]. Interestingly, the 
reactivation of ERVs observed following treatment of cells with DNA-
demethylating agents, such as 5-azacytidine (5-AZA) [31] has been proposed to 
be responsible for driving anti-tumour immunity in cancer patients treated with 
these drugs through innate sensing of ERV nucleic acids [13, 14]. 5-AZA drugs 
are thought to target mainly DNMT3A and DNMT3B, which can be increased in 
expression upon differentiation [32], in contrast to DNMT3L, which is not 
expressed in differentiated cells [33]. 
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Histone methyltransferases (HMTs) including SETDB1 (also known as ESET), 
SUV39h and G9a (also known as EHMT2) mediate retrotransposon repression 
through histone methylation [9, 10, 34]. The most relevant to this review is 
SETDB1 because it is required for retrotransposon repression in postembryonic 
tissues [35, 36]. Indeed, the finding that SETDB1 represses ERVs in committed 
mouse B-lineage cells, has led to a new paradigm that SETDB1 and potentially 
other histone modifiers remain important in differentiated cells [35]. 
Interestingly, loss of silent chromatin at SETDB1-regulated ERVs is not sufficient 
for their activation and the precise panel of ERVs reactivated in specific cell types 
depends on the transcription factors available [35]. HP1 too, which interacts 
with H3K9me3 [37, 38] and participates in heterochromatin spreading [39] has 
been implicated in silencing of ERVs including in differentiated cells [40, 41].  
 
The KAP1 and KRAB-ZNF repertoire 
The KAP1 and KRAB-ZNF (KRAB-zinc finger protein) system silences 
retrotransposons in early embryos and embryonic stem cells (ESCs) [12, 42, 43]. 
It has likely evolved in response to retrotransposon invasions [44] because 
KRAB-ZNF transcription factors are largely specific for transposon sequences 
[45-47] but now this pathway also participates in gene regulation [45, 48, 49]. 
KAP1 is recruited to transposons through the interaction of its RING, B-box and 
coiled–coil (RBCC) domain with the KRAB domain of KRAB-ZNFs. 
Transcriptional repression is mediated through co-factors such as SETDB1[50-
52], which prevents binding of transcriptional activators[53, 54]. There are 
several hundred KRAB-ZNFs [55], which can be viewed as a panel of effector 
proteins specific for foreign DNA in the same way that an antibody repertoire is 
specific for foreign antigens. While many KRAB-ZNFs have recently been 
matched to their target sequences through chromatin immunoprecipitation 
experiments [45-47], only a few have been functionally characterized. These 
include human ZNF91 and ZNF93, which recognize specific SVA and LINE1 
subfamily sequences, respectively [56]. The KAP1 and KRAB-ZNF pathway is 
functional in human and mouse ESCs and neural progenitor cells [42, 57-59] but 
little is known about its role in differentiated cells. However, one study showed 
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that KAP1 binds to certain ERV-K elements in human primary CD4+ T cells [59]. 
It was also reported that KAP1 and KRAB-ZFPs bind to several ERVs in mouse 
liver. Interestingly, while KAP1 knockout in the liver had little impact on the 
expression of these ERVs, several co-regulated cellular genes were affected [48]. 
This suggests that redundant mechanisms may converge to silence ERVs in 
differentiated cells [48]. Surprisingly, HSP90 has recently been implicated in the 
formation of a KAP1 repressor complex at ERVs [60]. Like KAP1, HSP90 is 
necessary to maintain silent chromatin at ERVs and prevent aberrant 
transcription of genes close to the ERVs that it regulates [49, 60]. Most 
interestingly, this is true not only in ESCs but also in differentiated macrophages 
[60]. The nucleosomal and remodeling deacetylase (NuRD) complex, which 
interacts with KAP1 has also been implicated in retrotransposon repression in 
differentiated cells [61]. 
 
Of note, not all ERV-derived sequences are subject to epigenetic silencing as 
some have been co-opted because their non-coding DNA regulatory elements, 
nucleic acids or even gene products benefit their hosts [5, 6, 62, 63]. Whether co-
opted ERVs are subject to spatial or temporal repression by KAP1 remains an 
open question. However, certain KRAB-ZNFs have been found to bind to co-
opted ERVs and to recruit transcriptional activators and pioneer factors, 
suggesting that these ZNFs function to switch on rather then switch off certain 
gene networks [45, 47]. 
 
Implications for immune regulation 
ERVs have been implicated in multiple cancers and autoimmune diseases, 
including ovarian and breast cancer, systemic lupus erythematosus and multiple 
sclerosis [64, 65]. There is some convincing evidence that ERVs can play a 
causative role in cancer when their LTRs escape epigenetic repression [66] and 
interestingly, this involves mainly primate-specific ERVs [67]. For example, 
cryptic enhancers and promoters that reside within ERVs can drive expression of 
oncogenes[66, 68]. 
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ERVs regulate the immune system in several ways. For example, double stranded 
RNA (dsRNA) produced from retrotransposons, following treatment of cancer 
cells with DNA methyltransferase inhibitors activates interferon through MDA5, 
MAVS and IRF7 [13, 14]. Cytoplasmic DNA resulting from reverse transcription 
also serves as an additional PAMP because it is detected by the cytosolic DNA 
sensor cGAS to activate type I interferon through STING [63, 69-72]. Likewise, 
Toll-like receptors contribute to ERV nucleic acid sensing [73]. Mutations within 
genes involved in nucleic acid metabolism including TREX1 are associated with 
autoimmune diseases [74], although such factors block classes of 
retrotransposons that are constitutively transcribed rather than those 
embedded within silent chromatin. In addition to innate immunity, ERVs can 
stimulate adaptive immunity too because their encoded gene products, which 
are necessary for their mobilization are subject to standard antigen processing 
and presentation pathways. For example, tumour-associated antigens (TAAs) 
can be derived from HERV-K envelope protein[75]. Such neo-antigens can evoke 
adaptive T cell and antibody responses [76], both of which have been 
demonstrated to regulate ERVs [15, 75].  
 
Overall, ERV regulatory sequences including solo LTRs have been described to 
contribute to cancer by driving oncogenes, whereas longer ERVs if resurrected 
(for example through 5-AZA treatment) may promote anti-tumour immunity 
through their nucleic acids and proteins. Exactly how sensing of ERV nucleic 
acids leads to anti-tumour immunity is not fully understood but remarkably, it 
has been shown that if cancer initiating cells are pretreated with 5-AZA drugs 
before their injection into mice, they form less tumours and this phenotype is 
dependent on MAVS[14]. Likewise, if B16 melanoma cells are pretreated with 5-
AZA before their injection into mice that receive anti-CTLA-4, they can stimulate 
complete tumour clearance[13]. Furthermore, interferon-responsive genes are 
upregulated in cancer patients treated with 5-AZA[77]. Interferon signaling is 
important presumably to promote apoptosis of cancer cells and to help to recruit 
cytotoxic T cells recognizing neo-antigens and other immune effectors to clear 
the tumour. It has also been shown that cytosolic RNA and DNA sensing of ERVs 
is necessary to induce T-independent B cell responses in mice[63]. This latter 
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work illustrates that ERVs have coevolved with their hosts to play a natural role 
in modulating the immune system. Overall, ERVs lie at the intersection of innate 
and adaptive immunity, due to their intrinsic immunogenicity. 
 
Concluding remarks 
While it was previously thought that histone marks are primarily required to 
silence retrotransposons only early in development[10, 50, 78, 79], where DNA 
methylation is reprogrammed[80, 81], recent evidence has led to a new 
paradigm whereby diverse epigenetic modifiers exert continuous roles in adult 
tissues. Here we discuss evidence that SETDB1, DNMTs, HP1, HSP90, the NuRD 
complex and potentially KAP1 and KRAB-ZNFs are some of these factors. 
Importantly, most of these regulators have only been studied in mouse models 
so far. A future understanding of the pathways operating in adult human tissues 
is essential for the development of innovative drugs. Targeted epigenetic 
modulation might prove a potent tool in the future to reactivate certain 
retrotransposons so that their nucleic acids and proteins could serve as natural 
PAMPs to signal danger to their host. Such drugs may be valuable to stimulate 
immunosurveillance in cancer patients in which immune activation pathways 
may be subdued or could be used in conjunction with standard vaccines in place 
of an adjuvant. Caution should be applied, however, to prevent unwanted effects 
of reactivated ERVs on the genome or transcriptome. 
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Figure Legends 
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Figure 1: Epigenetic factors repress retrotransposons in differentiated 
tissues, preventing transcription and sensing of non-self nucleic acids. In 
differentiated cells, epigenetic silencing of retrotransposons is maintained by 
incompletely characterized mechanisms. Factors implicated in maintaining 
histone and DNA methylation at retrotransposons are shown. See text for details. 
Uncharacterized factors are depicted in blue to illustrate that this is an emerging 
area of research. The addition of 5-AZA-based drugs results in the generation of 
dsRNA from retrotransposons and potentially cDNA as well through reverse 
transcription, both of which lead to innate immune activation. 
